Alumis Inc.
ALMS
株式のランク
#10425
Alumis Inc., a clinical stage biopharmaceutical company, focuses on the... Alumis Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of medicines for autoimmune disorders. The company offers envudeucitinib, a tyrosine kinase 2 (TYK2) inhibitor for the treatment of plaque psoriasis and systemic lupus erythematosus; and A-005, a central nervous system-penetrant allosteric TYK2 inhibitor that is in Phase 1 for the treatment of neuroinflammatory and neurodegenerative diseases. It also develops lonigutamab, a monoclonal antibody targeting IGF-1R for the treatment of thyroid eye diseases; and interferon regulatory factor 5 (IRF5) to address immune dysfunction. The company was formerly known as Esker Therapeutics, Inc. and changed its name to Alumis Inc. in January 2022. Alumis Inc. was incorporated in 2021 and is headquartered in South San Francisco, California.
株価
$6.15
最終同期: 2026-10-16
時価総額
$795.38M
変化（1日）
-2.61%
変化（1年）
170.70%
国
US
取引 Alumis Inc. (ALMS)
カテゴリー
Healthcare
の時価総額 Alumis Inc.(ALMS)
時価総額: $795.38M
October 2026時点で、Alumis Inc. の時価総額は $795.38M です。これは、当社のデータによると、Alumis Inc. が世界で10425th番目に価値のある企業であることを意味します。時価総額は、上場企業の発行済株式の総市場価値であり、企業の価値を測るためによく使用されます。
Alumis Inc. の時価総額の履歴（2023 から 2026 まで）
